170 related articles for article (PubMed ID: 33282745)
1. Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study.
Wei R; Dean DC; Thanindratarn P; Hornicek FJ; Guo W; Duan Z
Front Oncol; 2020; 10():596330. PubMed ID: 33282745
[TBL] [Abstract][Full Text] [Related]
2. Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.
Wei R; Thanindratarn P; Dean DC; Hornicek FJ; Guo W; Duan Z
J Orthop Res; 2020 Sep; 38(9):1952-1964. PubMed ID: 32162720
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value.
Thanindratarn P; Dean DC; Feng W; Wei R; Nelson SD; Hornicek FJ; Duan Z
Eur Spine J; 2020 Dec; 29(12):3214-3228. PubMed ID: 32691223
[TBL] [Abstract][Full Text] [Related]
4. Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma.
Wei J; Wu J; Yin Z; Li X; Liu Y; Wang Y; Wang Z; Xu C; Fan L
Front Oncol; 2022; 12():1048482. PubMed ID: 36601478
[TBL] [Abstract][Full Text] [Related]
5. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
Zhang L; Guo S; Schwab JH; Nielsen GP; Choy E; Ye S; Zhang Z; Mankin H; Hornicek FJ; Duan Z
PLoS One; 2013; 8(9):e75851. PubMed ID: 24086644
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of cyclin F/CCNF as an independent prognostic factor for poor survival in clear cell renal cell carcinoma.
Kwiatkowski M; Krajewski A; Durślewicz J; Buchholz K; Grzanka D; Gagat M; Zabrzyński J; Klimaszewska-Wiśniewska A
Sci Rep; 2024 Apr; 14(1):9280. PubMed ID: 38654021
[TBL] [Abstract][Full Text] [Related]
8. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
Feng Y; Shen J; Gao Y; Liao Y; Cote G; Choy E; Chebib I; Mankin H; Hornicek F; Duan Z
Oncotarget; 2015 May; 6(13):11139-49. PubMed ID: 25871477
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of p16, cyclin D1, Rb and MIB-1 levels in skull base chordoma and chondrosarcoma.
Liu JQ; Zhang QH; Wang ZL
World J Otorhinolaryngol Head Neck Surg; 2015 Sep; 1(1):50-56. PubMed ID: 29204540
[TBL] [Abstract][Full Text] [Related]
10. Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
Shen S; Dean DC; Yu Z; Hornicek F; Kan Q; Duan Z
J Cancer; 2020; 11(1):132-141. PubMed ID: 31892980
[No Abstract] [Full Text] [Related]
11. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
12. Proteomics Analysis Identified ASNS as a Novel Biomarker for Predicting Recurrence of Skull Base Chordoma.
Shen Y; Li M; Xiong Y; Gui S; Bai J; Zhang Y; Li C
Front Oncol; 2021; 11():698497. PubMed ID: 34540668
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma.
Zuccato JA; Patil V; Mansouri S; Liu JC; Nassiri F; Mamatjan Y; Chakravarthy A; Karimi S; Almeida JP; Bernat AL; Hasen M; Singh O; Khan S; Kislinger T; Sinha N; Froelich S; Adle-Biassette H; Aldape KD; De Carvalho DD; Zadeh G
Neuro Oncol; 2022 Mar; 24(3):442-454. PubMed ID: 34614192
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
15. CSPG4 as a prognostic biomarker in chordoma.
Schoenfeld AJ; Wang X; Wang Y; Hornicek FJ; Nielsen GP; Duan Z; Ferrone S; Schwab JH
Spine J; 2016 Jun; 16(6):722-7. PubMed ID: 26689475
[TBL] [Abstract][Full Text] [Related]
16. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
17. A comparison of cell-cycle markers in skull base and sacral chordomas.
Yakkioui Y; Temel Y; Creytens D; Jahanshahi A; Fleischeuer R; Santegoeds RG; Van Overbeeke JJ
World Neurosurg; 2014; 82(1-2):e311-8. PubMed ID: 23416769
[TBL] [Abstract][Full Text] [Related]
18. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
[TBL] [Abstract][Full Text] [Related]
20. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.
Naka T; Boltze C; Kuester D; Schulz TO; Schneider-Stock R; Kellner A; Samii A; Herold C; Ostertag H; Roessner A
Cancer; 2005 Sep; 104(6):1255-63. PubMed ID: 16078265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
